CRDF
Price
$3.98
Change
-$0.16 (-3.86%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
275.42M
6 days until earnings call
XFOR
Price
$1.80
Change
-$0.03 (-1.64%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
10.77M
6 days until earnings call
Interact to see
Advertisement

CRDF vs XFOR

Header iconCRDF vs XFOR Comparison
Open Charts CRDF vs XFORBanner chart's image
Cardiff Oncology
Price$3.98
Change-$0.16 (-3.86%)
Volume$19.52K
Capitalization275.42M
X4 Pharmaceuticals
Price$1.80
Change-$0.03 (-1.64%)
Volume$2.33K
Capitalization10.77M
CRDF vs XFOR Comparison Chart in %
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. XFOR commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Hold and XFOR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CRDF: $4.14 vs. XFOR: $1.83)
Brand notoriety: CRDF and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 150% vs. XFOR: 1785%
Market capitalization -- CRDF: $275.42M vs. XFOR: $10.77M
CRDF [@Biotechnology] is valued at $275.42M. XFOR’s [@Biotechnology] market capitalization is $10.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileXFOR’s FA Score has 2 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • XFOR’s FA Score: 2 green, 3 red.
According to our system of comparison, XFOR is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 4 TA indicator(s) are bullish while XFOR’s TA Score has 5 bullish TA indicator(s).

  • CRDF’s TA Score: 4 bullish, 6 bearish.
  • XFOR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XFOR is a better buy in the short-term than CRDF.

Price Growth

CRDF (@Biotechnology) experienced а -6.97% price change this week, while XFOR (@Biotechnology) price change was +22.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.76%. For the same industry, the average monthly price growth was +19.76%, and the average quarterly price growth was +29.65%.

Reported Earning Dates

CRDF is expected to report earnings on Oct 30, 2025.

XFOR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDF($275M) has a higher market cap than XFOR($10.8M). CRDF YTD gains are higher at: -4.608 vs. XFOR (-91.685). XFOR has higher annual earnings (EBITDA): 25.2M vs. CRDF (-51.7M). XFOR has more cash in the bank: 87M vs. CRDF (79.9M). CRDF has less debt than XFOR: CRDF (1.36M) vs XFOR (78M). XFOR has higher revenues than CRDF: XFOR (31.4M) vs CRDF (587K).
CRDFXFORCRDF / XFOR
Capitalization275M10.8M2,546%
EBITDA-51.7M25.2M-205%
Gain YTD-4.608-91.6855%
P/E RatioN/A0.71-
Revenue587K31.4M2%
Total Cash79.9M87M92%
Total Debt1.36M78M2%
FUNDAMENTALS RATINGS
CRDF vs XFOR: Fundamental Ratings
CRDF
XFOR
OUTLOOK RATING
1..100
7021
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9712
PRICE GROWTH RATING
1..100
3798
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for CRDF (69) in the null industry. This means that XFOR’s stock grew somewhat faster than CRDF’s over the last 12 months.

XFOR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRDF (100) in the null industry. This means that XFOR’s stock grew similarly to CRDF’s over the last 12 months.

XFOR's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for CRDF (97) in the null industry. This means that XFOR’s stock grew significantly faster than CRDF’s over the last 12 months.

CRDF's Price Growth Rating (37) in the null industry is somewhat better than the same rating for XFOR (98) in the Biotechnology industry. This means that CRDF’s stock grew somewhat faster than XFOR’s over the last 12 months.

CRDF's P/E Growth Rating (100) in the null industry is in the same range as XFOR (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to XFOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFXFOR
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
87%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SEGYY0.23N/A
N/A
SPT Energy Group Inc
BHTLF43.57N/A
N/A
Bechtle AG
CICOF1.76N/A
N/A
COSCO SHIPPING Holdings Co Ltd.
NYWKF1.56N/A
N/A
NTG Clarity Networks Inc.
GDNGY2.05-0.18
-8.07%
Gudang Garam Pt

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with QURE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-3.50%
QURE - CRDF
44%
Loosely correlated
-1.11%
NAMS - CRDF
44%
Loosely correlated
-2.46%
MRVI - CRDF
41%
Loosely correlated
+3.44%
NRIX - CRDF
40%
Loosely correlated
-0.86%
ORMP - CRDF
39%
Loosely correlated
-2.61%
More